CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock
Rhea-AI Summary
CAMP4 Therapeutics (Nasdaq: CAMP) priced an underwritten offering of 5,000,000 common shares at $6.00 per share, for gross proceeds of $30.0 million. The offering is expected to close on or about December 19, 2025, subject to customary closing conditions.
The company said net proceeds, together with existing cash and marketable securities, will be used to support continued development activities for its product candidates and for general corporate purposes. Leerink Partners is sole underwriter; participants include Janus Henderson Investors, Coastlands Capital, EcoR1 Capital, Trails Edge Capital Partners, Vivo Capital and a large mutual fund complex. A Form S-3 registration became effective on December 1, 2025.
Positive
- Gross proceeds of $30.0 million
- Participation from institutional investors including Janus Henderson and Vivo Capital
- Form S-3 registration effective Dec 1, 2025 enabling the offering
Negative
- Issuance of 5,000,000 shares will dilute existing shareholders
- Net proceeds reduced by underwriting discounts, commissions, and offering expenses
- Closing is subject to customary conditions, creating potential timing risk
News Market Reaction 8 Alerts
On the day this news was published, CAMP declined 12.90%, reflecting a significant negative market reaction. Argus tracked a trough of -11.1% from its starting point during tracking. Our momentum scanner triggered 8 alerts that day, indicating moderate trading interest and price volatility. This price movement removed approximately $50M from the company's valuation, bringing the market cap to $334M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: ADVM up 2.83%, while DTIL and PDSB are down 2.66% and 3.52%; no broad biotech trend matching CAMP’s +1.71% pre-news gain.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 12 | Inducement grants | Neutral | +4.0% | Stock options for 92,000 shares granted to four new employees. |
| Nov 14 | Inducement grant | Neutral | -2.7% | Inducement option for 80,000 shares to a new hire. |
| Nov 06 | Earnings and financing | Positive | +7.0% | Q3 2025 results plus private placement up to $100M and runway into 2027. |
| Oct 01 | Pipeline update | Positive | -1.7% | Initiation of GLP toxicology for CMP‑SYNGAP‑01 targeting Phase 1/2 in H2 2026. |
| Sep 10 | Private placement | Positive | +40.2% | Oversubscribed private placement of up to $100M to advance SYNGAP1 program. |
Financing and pipeline progress updates have often seen positive reactions, while routine HR/inducement items show smaller, mixed moves.
Over the last few months, CAMP reported Q3 2025 results with a private placement of up to $100M and cash of $75.3M as of Sept 30, 2025, which saw a 6.97% positive reaction. An oversubscribed private placement of up to $100M on Sep 10 drew a strong 40.2% move. Pipeline updates like GLP tox initiation for CMP‑SYNGAP‑01 on Oct 1 led to a modest decline. Inducement option grants in November and December produced smaller, mixed price responses. Today’s underwritten equity offering follows this series of capital-raising and development milestones.
Regulatory & Risk Context
An effective Form S-3 shelf filed on Nov 10, 2025 registers up to $300,000,000 of various securities and includes an ATM program for up to $100,000,000 of common stock through Leerink Partners, providing flexibility for future capital raises.
Market Pulse Summary
The stock dropped -12.9% in the session following this news. A negative reaction despite the added capital would fit a pattern where dilution concerns weigh against financing benefits. CAMP recently registered about 33.4 million shares for resale, representing roughly 69% of outstanding shares, and set up a $300,000,000 shelf with a $100,000,000 ATM. The new $30.0 million underwritten deal adds further supply. Past events show that while some financings drew strong gains, pipeline updates occasionally saw price weakness, so reactions can be uneven.
Key Terms
underwritten offering financial
common stock financial
Form S-3 regulatory
registration statement regulatory
prospectus supplement regulatory
base prospectus regulatory
AI-generated analysis. Not financial advice.
CAMBRIDGE, Mass., Dec. 18, 2025 (GLOBE NEWSWIRE) -- CAMP4 Therapeutics Corporation (“CAMP4” or the “Company”) (Nasdaq: CAMP), a clinical-stage biopharmaceutical company developing a pipeline of regulatory RNA-targeting therapeutics designed to upregulate gene expression with the goal of restoring healthy protein levels to treat a broad range of genetic diseases, today announced the pricing of its underwritten offering of 5,000,000 shares of its common stock at a price of
The offering is expected to close on or about December 19, 2025, subject to satisfaction of customary closing conditions. All of the securities to be sold in the offering are being offered by the Company.
CAMP4 currently anticipates using the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, primarily to support continued development activities for its product candidates, as well as general corporate purposes.
The financing includes participation from new and existing investors, including a large mutual fund complex, Janus Henderson Investors, Coastlands Capital, EcoR1 Capital, Trails Edge Capital Partners, and Vivo Capital.
Leerink Partners is acting as the sole underwriter for the offering.
A registration statement on Form S-3 (File No. 333-291432) relating to these securities has been filed with the Securities and Exchange Commission (the “SEC”) and became effective on December 1, 2025. This offering is being made solely by means of a prospectus supplement and accompanying prospectus. A prospectus supplement and accompanying base prospectus relating to and describing the terms of the offering will be filed with the SEC and available on the SEC’s website located at http://www.sec.gov. When available, copies of the prospectus supplement and the accompanying prospectus related to the offering may be obtained from Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525 ext. 6105, or by email at syndicate@leerink.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About CAMP4 Therapeutics
CAMP4 is developing disease-modifying treatments for a broad range of genetic diseases where amplifying healthy protein may offer therapeutic benefits. Our approach amplifies mRNA by harnessing a fundamental mechanism of how genes are controlled. To amplify mRNA, our therapeutic ASO drug candidates target regulatory RNAs (“regRNAs”), which act locally on transcription factors and are the master regulators of gene expression. CAMP4’s proprietary RAP Platform® enables the mapping of regRNAs and generation of therapeutic candidates designed to target the regRNAs associated with genes underlying haploinsufficient and recessive partial loss-of-function disorders, of which there are more than 1,200, in which a modest increase in protein expression may have the potential to be clinically meaningful.
Forward-Looking Statements
This press release contains forward-looking statements which involve risks, uncertainties and contingencies, many of which are beyond the control of the Company, which may cause actual results, performance, or achievements to differ materially from anticipated results, performance, or achievements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “potential” or “continue” or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words.
These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, the anticipated timing of the offering, market conditions and satisfaction of customary closing conditions related to the offering, risks and uncertainties related to market conditions; volatility in the trading price of the Company’s common stock; risks inherent in achieving regulatory milestones; the Company’s limited operating history, incurrence of substantial losses since the Company’s inception and anticipation of incurring substantial and increasing losses for the foreseeable future; the Company’s need for substantial additional financing to achieve the Company’s goals; the uncertainty of clinical development, which is lengthy and expensive, and characterized by uncertain outcomes, and risks related to additional costs or delays in completing, or failing to complete, the development and commercialization of the Company’s current product candidates or any future product candidates; delays or difficulties in the enrollment and dosing of patients in clinical trials; the impact of any significant adverse events or undesirable side effects caused by the Company’s product candidates; potential competition, including from large and specialty pharmaceutical and biotechnology companies; the Company’s ability to realize the benefits of the Company’s current or future collaborations or licensing arrangements and ability to successfully consummate future partnerships; the Company’s ability to obtain regulatory approval to commercialize any product candidate in the United States or any other jurisdiction, and the risk that any such approval may be for a more narrow indication than the Company seeks; the Company’s dependence on the services of the Company’s senior management and other clinical and scientific personnel, and the Company’s ability to retain these individuals or recruit additional management or clinical and scientific personnel; the Company’s ability to grow the Company’s organization, and manage the Company’s growth and expansion of the Company’s operations; risks related to the manufacturing of the Company’s product candidates, which is complex, and the risk that the Company’s third-party manufacturers may encounter difficulties in production; the Company’s ability to obtain and maintain sufficient intellectual property protection for the Company’s product candidates or any future product candidates the Company may develop; the Company’s reliance on third parties to conduct the Company’s preclinical studies and clinical trials; the Company’s compliance with the Company’s obligations under the licenses granted to the Company by others, for the rights to develop and commercialize the Company’s product candidates; risks related to the operations of the Company’s suppliers; and other risks and uncertainties described in the section “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, as well as other information the Company files with the SEC. The forward-looking statements in this press release are inherently uncertain and are not guarantees of future events. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond the Company’s control, you should not unduly rely on these forward-looking statements. The events and circumstances reflected in the forward-looking statements may not be achieved or occur and actual future results, levels of activity, performance and events and circumstances could differ materially from those projected in the forward-looking statements. Moreover, the Company operates in an evolving environment. New risks and uncertainties may emerge from time to time, and management cannot predict all risks and uncertainties. Investors, potential investors, and others should give careful consideration to these risks and uncertainties. Except as required by applicable law, the Company does not undertake to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.
Contacts
Investor Relations:
Sara Michelmore
Milestone Advisors
sara@milestone-advisorsllc.com
Media:
Jason Braco, Ph.D.
LifeSci Communications
jbraco@lifescicomms.com
FAQ
How many shares did CAMP4 (CAMP) offer and at what price?
What are the gross proceeds and expected closing date for the CAMP offering?
How does CAMP4 plan to use the net proceeds from the $30.0 million offering?
Who is the underwriter and which investors participated in CAMP4's offering?
Was the SEC registration effective for CAMP4's offering and when?
